EICHORPublic-registry site landscape for NCT06126497, “Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients”, a Major Depressive Disorder study sponsored by Suven Life Sciences Limited. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06126497 (registry record) |
| Study title | Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients |
| Official title | An Open-Label Study Evaluating the Safety and Efficacy of Ropanicant in Participants With Moderate to Severe Major Depressive Disorder |
| Sponsor | Suven Life Sciences Limited |
| Condition(s) | Major Depressive Disorder |
| Phase | PHASE2 |
| Listed sites | 10 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06126497.
Eichor generates a preliminary site-risk snapshot for NCT06126497 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Major Depressive Disorder trials
← Eichor home · All tracked trials · Major Depressive Disorder studies · Weekly briefs
